Global Long-Term Registry for Adults With Generalized Myasthenia Gravis Receiving Alexion Complement C5 Inhibitor Treatments

What this Trial Is About

This research aims to collect long-term data on patients with generalized myasthenia gravis gMG who are prescribed Alexion complement C5 inhibition therapies, including eculizumab Soliris and ravulizumab Ultomiris. It is an observational, multinational registry designed to monitor clinical outcomes and safety over time in a real-world setting. The study is led by Alexion Pharmaceuticals, Inc. and involves multiple centers worldwide. Participants who join the registry will have their medical history and gMG treatment history reviewed retrospectively at enrollment. After joining, data will be gathered prospectively during routine clinical care visits and through patient-reported outcomes, all collected electronically. The registry maintains observation and data collection for up to five years from the day of enrollment. During the study, participants will be asked to attend routine visits where their clinical status, including the Myasthenia Gravis Activities of Daily Living MG-ADL score, will be assessed. Researchers will track changes in these scores approximately five years after enrollment to understand long-term outcomes. The study does not involve any experimental treatments but monitors patients receiving prescribed Alexion therapies as part of their usual care.

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)